FLAGSHIP IS PRESENTING A POSTER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 34TH ANNUAL MEETINGNovember 6-10, 2019 Gaylord National Hotel and Convention Center, National Harbor, MD Flagship is presenting a scientific poster on November 8th at the meeting in...
WEBINAR – IMPROVING PD-L1 SCORING WITH IMAGE ANALYSISOctober 9, 2019 1 PM EDT/10 AM PDT on “Improving PD-L1 Scoring with Image Analysis”.
ANALYTICAL ADVANCEMENTS TO POWER BIOMARKER DEVELOPMENT TRACK PRESENTATION: ADDING VALUE TO TRADITIONAL IN VITRO DIAGNOSTICS (IVDS) AT WORLD CB&CDXSeptember 12, 2019 at 2:50pm The Renaissance Boston Waterfront, Boston, MA Speaker: Kelsey Weigel, PhD, Scientist II,...
WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist InterpretationCambridge, MA and Westminster, CO – April 12, 2021 — Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a...
Dr. Roberto Gianani and Michael Koratich Named to Key Medical and Pharma RolesWestminster, CO – March 10, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced strategic additions to its executive team. Dr. Roberto...
PUBLICATIONS/POSTERS
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
Key takeways: Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...